Bitcoin price today: dips below $112k, near 6-wk low despite Fed cut bets
THE WOODLANDS, TX - Autonomix Medical, Inc. (NASDAQ: AMIX), a medical device company specializing in neuromodulation technologies with a market capitalization of $4.1 million, has been granted a new patent by the European Patent Office (EPO). According to InvestingPro analysis, the company appears undervalued despite its shares falling 97% over the past year. Patent No. 3,226,792, titled "Systems And Methods For Regulating Organ and/or Tumor Growth Rates, Function, and/or Development," expands the company’s global patent portfolio to over 80 issued patents with an additional 40 pending.
The patent encompasses a variety of methods and systems for nerve and receptor monitoring, electrophysiological monitoring, and surgical procedures. These are integral to the systems that regulate prostate and tumor growth. Brad Hauser, CEO of Autonomix, expressed the company’s commitment to leveraging their growing patent portfolio to support future applications and expansion opportunities. Hauser highlighted the potential of the patented technology to address a range of conditions related to peripheral nerve bundles and pain management.
The newly patented technology can sense, ablate, and verify neurological traffic to the prostate and lower urinary tract organs (LUT), potentially slowing or reversing the growth of prostate glands or tumors. The systems and methods could also be applicable in treating other LUT diseases, such as chronic prostatitis and erectile dysfunction, by modulating neural activity and hormonal secretions. While the company maintains a strong liquidity position with a current ratio of 5.31, InvestingPro data shows it’s currently burning through cash reserves rapidly.
Autonomix is preparing to submit an Investigational Device Exemption (IDE) and to start U.S. clinical trials in 2025, aiming for a labeling indication to commercialize their Sensing and RF Ablation System in the U.S. for the treatment of pancreatic cancer pain.
The company’s platform system technology features a catheter-based microchip sensing array, which may offer greater sensitivity in detecting and differentiating neural signals than currently available technologies. Autonomix’s initial focus is on treating the debilitating pain caused by pancreatic cancer, with broader applications across various medical conditions anticipated.
The information in this article is based on a press release statement from Autonomix Medical, Inc. The technology discussed is investigational and has not yet been cleared for marketing in the United States. Forward-looking statements involve risks and uncertainties, and there can be no assurance that the potential treatments will prove to be effective. For deeper insights into AMIX’s financial health, valuation metrics, and growth potential, investors can access additional analysis through InvestingPro, which offers 8 more exclusive tips about the company’s performance and prospects.
In other recent news, Autonomix Medical, Inc. has made significant strides in its technological advancements and regulatory preparations. The company announced the completion of its Application Specific Integrated Circuit (ASIC) microchip design, following successful preclinical and bench testing. This development is crucial as it paves the way for manufacturing the microchip for human use and submitting an Investigational Device Exemption (IDE) to the FDA. Autonomix is also advancing its Sensing and RF Ablation System, which is set to undergo clinical trials in the United States for pancreatic cancer pain treatment starting in 2025. This follows the integration of the Apex 6 Radiofrequency Generator, a strategic acquisition from RF Innovations, Inc., which already holds FDA clearance.
The company plans to initiate these clinical trials as part of its strategy to secure a De Novo FDA approval by 2026. Autonomix has enlisted the expertise of renowned medical professionals to guide its development efforts. CEO Brad Hauser has expressed optimism about the potential impact of their technology on improving treatment options for pancreatic cancer pain, a condition with few effective solutions. The company’s platform technology, still in the investigational stage, includes a catheter-based microchip sensing array designed to enhance neural signal detection. These developments are part of Autonomix’s broader vision to address various medical conditions involving the peripheral nervous system.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.